TY - JOUR
T1 - Challenges to effective cancer nanotheranostics
AU - Melancon, Marites P.
AU - Stafford, R. Jason
AU - Li, Chun
N1 - Funding Information:
This work was supported in part by National Institutes of Health grants RC2 GM092599 , Center of Cancer Nanotechnology Excellence grant ( U54 CA151668 ), and the John S. Dunn Foundation . We thank Donald R. Norwood for editing the manuscript.
PY - 2012/12/10
Y1 - 2012/12/10
N2 - Advances in nanotechnology for oncology will arise from an increased understanding of the interaction between nanomaterials and biological systems; refinement of multifunctional nanocomposites for applications such as simultaneous imaging and therapy (theranostics); and harnessing of the unique physicochemical properties arising from nanoscale effects which distinguish them from small-molecular-weight molecules in the detection and destruction of cancer cells with high selectivity and efficiency. The major challenges in successful clinical translation of tumor specific nanoparticle delivery include overcoming various biological barriers and demonstrating enhanced therapeutic efficacy over the current standard of care in the clinic. For many nanoparticle mediated theranostic applications, image guidance can play a crucial role not only in exploiting the cancer specific imaging capabilities of these novel particles, but in planning, targeting, monitoring and verifying treatment delivery, thus enhancing the safety and efficacy of these emerging procedures.
AB - Advances in nanotechnology for oncology will arise from an increased understanding of the interaction between nanomaterials and biological systems; refinement of multifunctional nanocomposites for applications such as simultaneous imaging and therapy (theranostics); and harnessing of the unique physicochemical properties arising from nanoscale effects which distinguish them from small-molecular-weight molecules in the detection and destruction of cancer cells with high selectivity and efficiency. The major challenges in successful clinical translation of tumor specific nanoparticle delivery include overcoming various biological barriers and demonstrating enhanced therapeutic efficacy over the current standard of care in the clinic. For many nanoparticle mediated theranostic applications, image guidance can play a crucial role not only in exploiting the cancer specific imaging capabilities of these novel particles, but in planning, targeting, monitoring and verifying treatment delivery, thus enhancing the safety and efficacy of these emerging procedures.
KW - Barriers
KW - Nanoparticles
KW - Photothermal ablation therapy
KW - Targeting
UR - http://www.scopus.com/inward/record.url?scp=84869508752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869508752&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2012.07.045
DO - 10.1016/j.jconrel.2012.07.045
M3 - Article
C2 - 22906841
AN - SCOPUS:84869508752
SN - 0168-3659
VL - 164
SP - 177
EP - 182
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 2
ER -